CenExel Announces Formation of Task Forces to Advance Patient-Focused Clinical Research

DRAPER, UTAH / ACCESS Newswire / October 16, 2025 / CenExel, a leading, wholly owned clinical research site network, announces the formation of the CenExel Task Forces, designed to strengthen collaboration, enhance scientific innovation, and further elevate patient care across its nationwide network.

The new CenExel Task Forces, which are focused on Psychiatry, Pain, and Metabolic research, unite key opinion leaders and operational experts from across CenExel’s nineteen Centers of Excellence to advance clinical research through shared expertise, strategic alignment, and collaboration.

Task Force Leadership

These therapeutic task forces will drive CenExel’s mission to put patients first by optimizing trial design and delivery, ensuring access to innovative therapies, and reinforcing consistency and quality across the network. The initiative also strengthens the partnership between scientific and operational leaders, enabling CenExel to provide sponsors and CROs with even greater data quality and reliability.

“Our leadership team is the backbone of CenExel,” said Ryan Brooks, CenExel’s Chief Executive Officer. “These new Task Forces harness the collective expertise and compassion of our most experienced clinicians and researchers. By bringing them together to share insights and align strategy, we’re ensuring that every decision – scientific, operational, and commercial – ultimately support the patients in our communities who trust us with their care.”

In conjunction with the Task Force initiative, CenExel also announced several leadership appointments that reflect the company’s continued investment in operational excellence and scientific depth:

The Task Forces will convene regularly to align scientific and operational priorities: monthly full-team meetings to share strategy and insights, biweekly subgroup sessions to focus on therapeutic or functional areas, and quarterly reviews with executive leadership to guide network-wide growth and innovation.

CenExel’s establishment of these Task Forces reflects its ongoing commitment to advancing clinical research with a patient-first mindset by combining scientific rigor, compassionate care, and deep community engagement to deliver meaningful breakthroughs for patients and their families.

Contact Information
Sara Koeblin
Director of Corporate Communications
s.koeblin@cenexel.com
(617) 639-6075

SOURCE: CenExel Research

View the original press release on ACCESS Newswire

Staff

Recent Posts

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…

21 minutes ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn…

21 minutes ago

Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…

22 minutes ago

A Christmas Message to the DEA’s Diversion Anti Marijuana Cabal

This Christmas season, President Trump's executive action to advance rescheduling and medical research has finally…

3 hours ago

Kanazawa University research: High-speed AFM imaging reveals how brain enzyme forms dodecameric ring structure

KANAZAWA, Japan, Dec. 26, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa…

9 hours ago

Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026

LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura's…

15 hours ago